Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
How Avast Helps Protect Millions From Online Scams, Malware, and Phishing in 2025 - Report by Expert Consumers
-
Metamorphosis Collective Announces Revolutionary 12 Week Program for High Achieving Women
-
The Underfront Co. Announces Wilmington's New Cocktail Destination
-
AdSolve Media Named Best Digital Marketing Agency in Edmonton
-
From Galloping Messengers to One-Click Delivery: The Lychee Journey from Chang'an to Today.
-
Harrah's Northern California Presents: Merry Millions - Win Up to $1 Million In Cash!
-
Springfield Energy Founder Kevin Okyere Calls for Shared Action as 12% of Ghanaians Face Food Insecurity
-
Pinnacle Funding Network Expands National DSCR Platform as Rates Hit Two-Year Low
-
Local Chattanooga Author Stephanie Pleasant Releases Powerful Memoir "Vestiges of Light"
-
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
-
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
-
Crypto News (Live): From $0.0075 to $0.50? Blazpay’s AI Presale Heats Up as Solana and BNB Investors Seek New Gains
-
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
-
Importance of Management Review Reports for ISO 27001 Certification
-
New to The Street Show #694 to Broadcast Tonight at 6:30 PM EST as Sponsored Programming on Bloomberg TV Featuring Stardust Power (NASDAQ:SDST), Spartan Equipment, Roadzen (NASDAQ:RDZN), Aeries Techno
-
Get Me to Costa Rica! Offers Life-Changing Travel Experience
-
Dr. Beran Parry and the Advanced Bio Solutions Group Become Global Natural Medicine Leaders!
-
HKUST Holds Congregation 2025 Conferring Honorary Doctorates on Five Distinguished Leaders
-
Unlock SEO Success with the New Search Atlas Wordpress Plugin
-
COME Mining Unleashes the Next Generation of Cloud Mining -- Powering BTC Machines with XRP and Earning Daily Rewards
-
Joshua Washington's Lee Malveaux Rolls Out S.O.K.R.A.H. Framework for Enterprise Teams
-
Raconteuse Skincare Unveils Sustainable Rituals That Blend Nature, Science, and Storytelling
-
Modern Renovation Trends Transforming Ottawa Homes in 2025
-
Sify Technologies to announce Financial Results for Second Quarter FY 2025-26 on Saturday, October 25, 2025
-
Slangate Pioneering Financial Fraud Recovery with Technology and Global Expertise
-
13th Annual Energy Day Festival Sparks STEM Interest Among Houston Students
-
Cupshe Unveils their For the Plot Party Collection in Collaboration with The Secret Lives of Mormon Wives Stars Jennifer Affleck, Demi Engemann, and Layla Taylor
-
Trivolve Tech and Quixy Launch Forensic Management System (FMS) on Cardano Mainnet
-
Liangzhu, where time speaks: Expats explore roots of Chinese civilization
-
Michael Green, Chief Strategist at Simplify Asset Management, joins WealthVest: The Weekly Bull & Bear Podcast
-
Crosby Brownlie Expands its Syracuse Location to Support Regional Growth
-
The 6th International Ancient Capitals Forum Kicks off in Luoyang, Focusing on the Sustainable Development of Ancient Capitals
-
/C O R R E C T I O N -- Express Wash Concepts/
-
Maple Financial Announces Strategic Equity Investment from Nesto Group via CMLS
-
Darkness to Light Expands National Scholarship Program Empowering Child Protection Leaders
-
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy
-
Medome Launches New Medical Industry: Personal Health Intelligence TM - AI-Powered Personal Health Records to Usher In New Era of DIY Healthcare for ALL Americans
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer W
-
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
-
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Tri
-
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTI
-
BexBack Launches No KYC, 100x Leverage, and $50 Welcome Bonus for Easy Crypto Futures Trading!
-
Nasdaq Halts Platinum Analytics Cayman Limited
-
Nasdaq Halts Etoiles Capital Group Co., Ltd.
-
Nasdaq Halts Pitanium Limited
-
Vakiav Launches their First Window Smart Bird Feeder Designed for Effortless Setup and Instant Connection
-
Astra Bitcoin: Dr. Antoun Toubia Launches a Revolutionary Asset-Backed Ecosystem Built on Ethereum
